tiprankstipranks
Novanta (NOVT)
NASDAQ:NOVT

Novanta (NOVT) AI Stock Analysis

214 Followers

Top Page

NOVT

Novanta

(NASDAQ:NOVT)

Select Model
Select Model
Select Model
Neutral 62 (OpenAI - 5.2)
Rating:62Neutral
Price Target:
$125.00
▲(5.83% Upside)
Action:ReiteratedDate:02/24/26
The score is anchored by solid financial foundations (notably deleveraging) and constructive technical momentum, plus a bullish FY2026 outlook for margin and cash flow recovery from management. These positives are offset by the weak 2025 cash flow performance and a very expensive valuation (high P/E), which raises downside sensitivity if execution on the cash and margin rebound falls short.
Positive Factors
Deleveraging & Net Cash Position
Novanta's materially improved leverage and expanded equity in 2025 signal a stronger capital structure and lower financing risk. A healthier balance sheet increases durable financial flexibility to fund R&D, absorb shocks, and pursue strategic investments or acquisitions without urgent refinancing needs.
Negative Factors
Weakened Operating & Free Cash Flow
A sharp drop in operating and free cash flow materially reduces financial flexibility and the cushion for capex, working capital needs, and M&A. If cash conversion doesn't recover as guided, the company may need to reallocate capital or delay investments, weakening longer‑term growth options.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraging & Net Cash Position
Novanta's materially improved leverage and expanded equity in 2025 signal a stronger capital structure and lower financing risk. A healthier balance sheet increases durable financial flexibility to fund R&D, absorb shocks, and pursue strategic investments or acquisitions without urgent refinancing needs.
Read all positive factors

Novanta (NOVT) vs. SPDR S&P 500 ETF (SPY)

Novanta Business Overview & Revenue Model

Company Description
Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. The com...
How the Company Makes Money
Novanta makes money primarily by selling engineered components, modules, and subsystems to OEM customers that incorporate Novanta technology into their own branded equipment. Revenue is generated from (1) product sales of photonics and laser-relat...

Novanta Key Performance Indicators (KPIs)

Any
Any
Revenue by Geography
Revenue by Geography
Chart InsightsNovanta's top-line is being driven by the U.S., which accounts for the bulk of revenue and has shown consistent acceleration; non-U.S. markets—notably China and Rest of Europe—have rebounded recently, helping offset weakness in Germany and small 'Other' markets. Management's booking growth and surging design wins validate the geographic recovery and support mid-single-digit organic guidance, but call details flag an underlying organic revenue contraction and Precision Medicine softness that could blunt near-term upside if bookings don't convert.
Data provided by:The Fly

Novanta Earnings Call Summary

Earnings Call Date:Feb 23, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call featured strong operational momentum: record revenue, broad-based double-digit bookings, significant new product traction, improved backlog, adjusted EBITDA and EPS growth, a net cash position, and robust 2026 guidance (revenue, margins, EBITDA, and cash flow). The main negatives were temporary and operational: Q4 margin compression, higher working capital and inventory from prioritized customer deliveries and regional manufacturing transfers, and a sharp Q4 cash flow decline. Management provided clear remediation actions (cost adjustments in January, completion of transfers by end of Q2) and reiterated confidence in margin expansion and cash rebound in 2026. On balance, the positive indicators and expected recovery outweigh the transitory headwinds.
Positive Updates
Record Quarterly and Full-Year Revenue
Q4 record revenue with 9% reported growth, 2% organic growth, and 4% sequential growth; full-year 2025 revenue of $981 million (company's largest year ever).
Negative Updates
Gross Margin Compression in Q4
Q4 non-GAAP adjusted gross margin declined to 45.5% from 47% in prior year (down 150 bps YoY and down 100 bps sequentially); management attributed >100 bps impact to deliberate decision to prioritize customer deliveries over timing of regional manufacturing transfers.
Read all updates
Q4-2025 Updates
Negative
Record Quarterly and Full-Year Revenue
Q4 record revenue with 9% reported growth, 2% organic growth, and 4% sequential growth; full-year 2025 revenue of $981 million (company's largest year ever).
Read all positive updates
Company Guidance
Management guided FY‑2026 GAAP revenue of $1,030–$1,050M (4–6% organic growth) with Q1 revenue $250–$255M (organic +1% to +3%, reported +7% to +9%) and sequential organic acceleration to ~+5%–+7% in Q2 and similar in the back half; adjusted gross margin is expected to be ~47% for the year (~+100 bps vs 2025) with Q1 at ~46.5%. They forecast R&D+SG&A of $294–$298M (~28% of sales) and Q1 opex of ~$76–$77M (~30% of sales), depreciation ~$17M FY, stock compensation ~$38M FY (Q1 ~$12M, Q2 ~$11M, then ~ $8M/quarter). Adjusted EBITDA is guided to $245–$250M (~24% margin, low double‑digit growth) with Q1 adjusted EBITDA $56–$58M (up 12–17% YoY); interest expense ~ $8M FY (~$2M Q1); non‑GAAP tax ~21% FY (19–20% Q1); diluted shares ~41M; diluted EPS $3.50–$3.65 FY (up to 11% YoY, including a $0.22–$0.24 headwind from the equity raise and a one‑time $0.14 equity‑grant impact), and Q1 adj. EPS $0.75–$0.80 (up ~8% YoY). Finally, operating cash flow is expected to rebound to $145–$185M for FY‑2026 (Q1 cash conversion >100% of GAAP net income), with regional manufacturing transfers to be completed by end of Q2.

Novanta Financial Statement Overview

Summary
Strong multi-year revenue growth and a materially improved leverage profile (net cash position supported by lower debt-to-equity), but 2025 showed meaningful pressure in profitability (EBITDA margin compression) and a sharp deterioration in operating/free cash flow, which is a key near-term risk.
Income Statement
67
Positive
Balance Sheet
78
Positive
Cash Flow
46
Neutral
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue980.60M949.25M881.66M860.90M706.79M
Gross Profit435.28M421.55M399.90M378.47M300.33M
EBITDA153.05M179.86M169.92M160.62M125.47M
Net Income53.83M64.09M72.88M74.05M50.33M
Balance Sheet
Total Assets1.81B1.39B1.23B1.24B1.23B
Cash, Cash Equivalents and Short-Term Investments380.87M113.99M105.05M100.11M117.39M
Total Debt341.61M471.00M404.56M489.38M493.40M
Total Liabilities492.82M642.81M552.60M663.63M706.59M
Stockholders Equity1.31B745.70M673.46M577.59M521.29M
Cash Flow
Free Cash Flow48.43M141.35M100.11M71.14M72.45M
Operating Cash Flow64.06M158.51M120.08M90.78M94.63M
Investing Cash Flow-74.32M-208.19M-19.89M-42.54M-306.70M
Financing Cash Flow276.33M56.94M-97.85M-60.15M204.75M

Novanta Technical Analysis

Technical Analysis Sentiment
Negative
Last Price118.11
Price Trends
50DMA
132.24
Negative
100DMA
124.52
Negative
200DMA
121.41
Negative
Market Momentum
MACD
-4.94
Positive
RSI
42.98
Neutral
STOCH
25.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NOVT, the sentiment is Negative. The current price of 118.11 is below the 20-day moving average (MA) of 121.48, below the 50-day MA of 132.24, and below the 200-day MA of 121.41, indicating a bearish trend. The MACD of -4.94 indicates Positive momentum. The RSI at 42.98 is Neutral, neither overbought nor oversold. The STOCH value of 25.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NOVT.

Novanta Risk Analysis

Novanta disclosed 38 risk factors in its most recent earnings report. Novanta reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Novanta Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$7.29B44.0721.34%0.16%13.13%24.02%
77
Outperform
$7.31B41.3518.74%11.55%1745.46%
74
Outperform
$5.43B24.7412.39%1.82%56.52%
68
Neutral
$4.37B27.5816.91%9.37%15.70%
68
Neutral
$5.14B155.811.11%1.43%-8.07%63.50%
62
Neutral
$4.21B80.885.84%4.07%-12.34%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NOVT
Novanta
118.11
-10.54
-8.19%
ESE
Esco Technologies
281.37
121.06
75.52%
OSIS
OSI Systems
265.51
67.24
33.91%
PLXS
Plexus
202.54
72.49
55.74%
ST
Sensata
35.22
10.98
45.32%
VICR
Vicor
161.00
112.43
231.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 24, 2026